Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Proteins with expanded polyglutamine repeats cause Huntington's disease and other neurodegenerative diseases. Transcriptional dysregulation and loss of function of transcriptional co-activator proteins have been implicated in the pathogenesis of these diseases. Huntington's disease is caused by expansion of a repeated sequence of the amino acid glutamine in the abnormal protein huntingtin (Htt). Here we show that the polyglutamine-containing domain of Htt, Htt exon 1 protein (Httex1p), directly binds the acetyltransferase domains of two distinct proteins: CREB-binding protein (CBP) and p300/CBP-associated factor (P/CAF). In cell-free assays, Httex1p also inhibits the acetyltransferase activity of at least three enzymes: p300, P/CAF and CBP. Expression of Httex1p in cultured cells reduces the level of the acetylated histones H3 and H4, and this reduction can be reversed by administering inhibitors of histone deacetylase (HDAC). In vivo, HDAC inhibitors arrest ongoing progressive neuronal degeneration induced by polyglutamine repeat expansion, and they reduce lethality in two Drosophila models of polyglutamine disease. These findings raise the possibility that therapy with HDAC inhibitors may slow or prevent the progressive neurodegeneration seen in Huntington's disease and other polyglutamine-repeat diseases, even after the onset of symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The progression of neurodegeneration is slowed by treatment with deacetylase inhibitors, further emphasizing the impor- tance of a controlled balance of protein acetylation and deacetylation in cellular functions in diverse tissues (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
In the citing paper
“A recent report showed that neurodegeneration triggered by expression of the polyglutamine-containing protein Httex1p involves inhibition of CBP/p300- and PCAF-AT activities (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
Citations
Cites
Targeted gene expression as a means of altering cell fates and generating dominant phenotypes
Brand, A. H., & Perrimon, N. (1993) · Development · doi:10.1242/dev.118.2.401 · Cited by 9,612
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595 · cited 1×
“We found that even normal repeat Htt can bind to and inhibit acetyltransferase activity ( Figs 1 and 2 ), so why is pathology associated with only expanded repeat Htt? Mutant Htt can be proteolytically processed; the pathogenic fragment localizes to the nucleus, where it is capable of inhibiting acetyltransferase acti…”
BackgroundA p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479 · cited 1×
“, pGST–P/CAF-AT domain (encoding amino acids 87–768), and pcDNA3 containing the cDNA for P/CA”
MethodGlutamine Repeats and Neurodegeneration
Zoghbi, H. Y., & Orr, H. T. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.217 · Cited by 1,309 · cited 1×
“The aetiology of several other neurodegenerative diseases, including spinocerebellar ataxia I and Kennedy's disease, also involves expansion of a polyglutamine repea”
BackgroundHistone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Nucifora, F. C., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., et al. (2001) · Science · doi:10.1126/science.1056784 · Cited by 1,094
Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062 · cited 1×
“We previously found that a fragment of mutant Htt interacts directly with CBP, which contains an acetyltransferase domain and is a co-activator of numerous promoter”
BackgroundSelf-citationLuo, L., Liao, Y. J., Jan, L. Y., & Jan, Y. N. (1994) · Genes & Development · doi:10.1101/gad.8.15.1787 · Cited by 983
Cited by
Items 501–600 of 1,000
Mechanisms of cell death in polyglutamine expansion diseases
Lipinski, M. M. (2003) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.09.008 · Cited by 49
Epigenetics-Based Therapeutics for Neurodegenerative Disorders
Xu, Z., Li, H., & Jin, P. (2012) · Current Geriatrics Reports · doi:10.1007/s13670-012-0027-0 · Cited by 50
Perturbation of U2AF65/NXF1-mediated RNA nuclear export enhances RNA toxicity in polyQ diseases
Tsoi, H., Lau, T. C., Lau, K., & Chan, H. Y. E. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr297 · Cited by 48
Joshi, A. S., Singh, V., Gahane, A., & Thakur, A. K. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00545 · Cited by 47
Reactive Species in Huntington Disease: Are They Really the Radicals You Want to Catch?
Bono-Yagüe, J., Gómez-Escribano, A. P., Millán, J. M., & Vázquez‐Manrique, R. P. (2020) · Antioxidants · doi:10.3390/antiox9070577 · Cited by 55
Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis
Glajch, K. E., & Sadri‐Vakili, G. (2015) · Journal of Huntington s Disease · doi:10.3233/jhd-140134 · Cited by 52
Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein
Hoshino, M., Tagawa, K., Okuda, T., Murata, M., Oyanagi, K., Arai, N., Mizutani, T., Kanazawa, I., Wanker, E. E., & Okazawa, H. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01991.x · Cited by 48
Kennedy's disease: pathogenesis and clinical approaches
Greenland, K. J., & Zajac, J. D. (2004) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2004.00588.x · Cited by 55
Potential application of grape derived polyphenols in Huntington’s disease
Wang, J., Pfleger, C. M., Friedman, L. G., Vittorino, R., Zhao, W., Qian, X., Conley, L. M., Ho, L., & Pasinetti, G. M. (2010) · Translational Neuroscience · doi:10.2478/v10134-010-0022-y · Cited by 48
“Overexpressing disease-associated aggregation-prone proteins has been used previously to model aspects of HD in drosophila [32–35].”
Huntington's disease, calcium, and mitochondria
Giacomello, M., Hudec, R., & Lopreiato, R. (2011) · BioFactors · doi:10.1002/biof.162 · Cited by 55
Spektor, B., Miller, D. W., Hollingsworth, Z. R., Kaneko, Y. A., Solano, S. M., Johnson, J. M., Penney, J. B., Young, A. B., & Luthi‐Carter, R. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00216-4 · Cited by 53
Enhanced Neuronal Glucose Transporter Expression Reveals Metabolic Choice in a HD Drosophila Model
Besson, M. T., Alegría, K., Garrido-Gerter, P., Barros, L. F., & Liévens, J.-C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118765 · Cited by 50
“The transgenic DrosophilaHDmodel used in this study has been widely exploited; it carried the exon 1 of the human mutated Huntingtin with 93 CAG repeats [40, 43].”
MethodDJ-1 modulates aggregation and pathogenesis in models of Huntington's disease
Sajjad, M. U., Green, E. W., Miller‐Fleming, L., Hands, S. L., Herrera, F., Campesan, S., Khoshnan, A., Outeiro, T. F., Giorgini, F., & Wyttenbach, A. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt466 · Cited by 54
Vittori, A., Breda, C., Repici, M., Orth, M., Roos, R. A. C., Outeiro, T. F., Giorgini, F., Hollox, E. J., & the REGISTRY investigators of the European Huntington's Disease Network (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu022 · Cited by 47
“The w;+; UASHttQ93 exon1 line (43) was a gift from J.”
BackgroundAnsaloni, A., Wang, Z., Jeong, J. S., Ruggeri, F. S., Dietler, G., & Lashuel, H. A. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307510 · Cited by 48
Upcoming Meetings Related to Huntington's Disease
Glajch, K. E., & Sadri‐Vakili, G. (2015) · Journal of Huntington s Disease · doi:10.3233/jhd-159001 · Cited by 48
Sharma, S., Kumar, K., Deshmukh, R. R., & Sharma, P. L. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.06.038 · Cited by 54
Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics
Ross, C. A., & Shoulson, I. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70800-4 · Cited by 48
“Several therapeutic trials of HDAC inhibitors have been conducted in HD mouse or fly models [33,34] and a safety and tolerability study of the HDAC inhibitor phenylbutyrate has been conducted in HD patients.”
BackgroundA Drosophila ortholog of the human MRJ modulates polyglutamine toxicity and aggregation
Fayazi, Z. S., Ghosh, S., Marion, S. M., Bao, X., Shero, M., & Kazemi‐Esfarjani, P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.015 · Cited by 50
Perrimon, N., Friedman, A. A., Mathey-Prévôt, B., & Eggert, U. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.006 · Cited by 48
“For example, the potency of relevant small molecules has been evaluated in Drosophila models of Huntington’s [4] Parkinson’s [ 5 ] and Alzheimer’s [6] diseases.”
BackgroundSpinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives
Katsuno, M., Adachi, H., Tanaka, F., & Sobue, G. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0530-7 · Cited by 49
“HDAC inhibitors, which restore histone acetylation by CBP, improve transcriptional activity and ameliorate polyQ-induced neurodegeneration in a cell model of SBMA [96] as well as in a fly model of HD [97], although this is of limited therapeutic benefit in a mouse model of HD due to toxicity [98].”
BackgroundLearning, Memory, and Transcription Factors
Johnston, M. V., Alemi, L., & Harum, K. H. (2003) · Pediatric Research · doi:10.1203/01.pdr.0000049517.47493.e9 · Cited by 53
Huntington’s disease: Neural dysfunction linked to inositol polyphosphate multikinase
Ahmed, I., Sbodio, J. I., Harraz, M. M., Tyagi, R., Grima, J. C., Albacarys, L. K., Hubbi, M. E., Xu, R., Kim, S., Paul, B. D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511810112 · Cited by 46
Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.
Martin, B., Golden, E., Keselman, A., Stone, M., Mattson, M. P., Egan, J. M., & Maudsley, S. R. (2008) · PubMed · doi:10.14670/hh-23.237 · Cited by 55
“The polyglutamine expansion that occurs in HD has been shown to induce widespread repression of gene transcription and a potent reduction in histone acetylation (Steffan et al., 2001).”
BackgroundYeh, H. H., Young, D. P., Gelovani, J. G., Robinson, A., Davidson, Y. S., Herholz, K., & Mann, D. M. A. (2013) · Brain Research · doi:10.1016/j.brainres.2013.02.012 · Cited by 50
Emerging roles of epigenetic mechanisms in Parkinson’s disease
Habibi, E., Masoudi‐Nejad, A., Abdolmaleky, H. M., & Haggarty, S. J. (2011) · Functional & Integrative Genomics · doi:10.1007/s10142-011-0246-z · Cited by 55
“Huntington’s disease Htt ↓ Human cell culture ⁄Drosophila model (Steffan et al. 2001), Human cell culture (Sugars et al.”
BackgroundMethodAβ43 is neurotoxic and primes aggregation of Aβ40 in vivo
Burnouf, S., Gorsky, M. K., Dols, J., Grönke, S., & Partridge, L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1419-y · Cited by 52
“To investigate whether neuronal expression of Aβ resulted in neuronal degeneration, we used the quantitative pseudopupil technique to analyse the loss of photoreceptor neurons from the fly compound eye [8, 14, 35].”
Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease
Leuti, A., Laurenti, D., Giampà, C., Montagna, E., Dato, C., Anzilotti, S., Melone, M. A. B., Bernardi, G., & Fusco, F. R. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.016 · Cited by 46
“…gene transcription has been hypothesized to contribute to neuronal loss in HD (Jiang et al., 2003; Kazantsev et al., 1999; Nucifora et al., 2001; Steffan et al., 2000, 2001) and a decreased transcription of CREB-regulated genes was observed in HD transgenic animals (Luthi-Carter et al., 2000;…”
BackgroundXu, F., Kula-Eversole, E., Iwanaszko, M., Hutchison, A. L., Dinner, A., & Allada, R. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.015 · Cited by 46
“…mechanisms of mHtt pathogenesis are conserved, including mTor (Ravikumar et al., 2004), histone acetylation (Ferrante et al., 2003; Hockly et al., 2003; Steffan et al., 2001), SUMOylation/ ubiquitination (Steffan et al., 2004), and axonal transport (Gunawardena et al., 2003; Smith et al., 2014).”
Vanommeslaeghe, K., Proft, F. D., Loverix, S., Tourwé, D., & Geerlings, P. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.001 · Cited by 56
Bolger, T. A., Zhao, X., Cohen, T. J., Tsai, C., & Yao, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704182200 · Cited by 54
Combating neurodegenerative disease with chemical probes and model systems
Narayan, P. S., Ehsani, S., & Lindquist, S. L. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1663 · Cited by 61
McCullough, S. D., Xu, X., Dent, S., Bekiranov, S., Roeder, R. G., & Grant, P. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218331110 · Cited by 49
“Interestingly, experiments in other polyglutamine expansion disorder models have indicated that the formation of NIs is not affected by treatment with SAHA (40), nicotinamide (41), or sodium butyrate (40, 42).”
BackgroundFodale, V., Kegulian, N. C., Verani, M., Cariulo, C., Azzollini, L., Petricca, L., Daldin, M., Boggio, R., Padova, A., Kuhn, R. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112262 · Cited by 42
“Although the precise mechanisms regulating N-terminal HTT conformation are only starting to be understood,the N17 region is subject to post-translational modifications (PTMs), including phosphorylation, acetylation, ubiquitination and SUMOylation which significantly alter HTT N-terminal fragment biological properties…”
BackgroundNeuroprotection for Huntington’s Disease: Ready, Set, Slow
Hersch, S. M., & Rosas, H. D. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.003 · Cited by 54
Epigenetic Treatment of Neurological Disease
Gray, S. G. (2011) · Epigenomics · doi:10.2217/epi.11.67 · Cited by 46
Promoter-Associated Noncoding RNA from the CCND1 Promoter
Song, X., Wang, X., Arai, S., & Kurokawa, R. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-376-9_39 · Cited by 45
Self-citationGiampà, C., DeMarch, Z., D’Angelo, V., Morello, M., Martorana, A., Sancesario, G., Bernardi, G., & Fusco, F. R. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04545.x · Cited by 47
Role of Mitochondrial Dysfunctions in Neurodegenerative Disorders: Advances in Mitochondrial Biology
Kathiresan, D. S., Balasubramani, R., Marudhachalam, K., Jaiswal, P., Ramesh, N., Suruthi, G. S., Moorthi, P. V., & Vijayan, M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04469-x · Cited by 52
“The antioxidant system’s inefficiency may result from the mtHtt protein, which reduces acetylase activity through CBP/p300 dimer interaction [290, 291] and affects Nrf2 stability and cellular localization [292].”
Epigenetic modifications in trinucleotide repeat diseases
Evans‐Galea, M. V., Hannan, A. J., Carrodus, N. L., Delatycki, M. B., & Saffery, R. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.07.007 · Cited by 54
Class IIA HDACs in the regulation of neurodegeneration
Majdzadeh, N. (2008) · Frontiers in Bioscience · doi:10.2741/2745 · Cited by 44
“elegans, drosophila and murine models of polyglutamine expansion diseases rescues the pathological hallmark of the disease (7-10).”
BackgroundDysfunction of Wild-Type Huntingtin in Huntington disease
Cattaneo, E. F. (2003) · Physiology · doi:10.1152/nips.01410.2002 · Cited by 44
“In addition, it was shown that the poly-Gln-containing domain of huntingtin directly binds to two distinct proteins, CBP and p300/CBP-associated factor (P/CAF) and inhibits their acetyltransferase activity, anticipating the possibility of a reduced histone acetylation as demonstrated in vitro (18).”
BackgroundLiévens, J.-C., Iché-Torres, M., Laval, M., Faivre‐Sarrailh, C., & Birman, S. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm360 · Cited by 53
“The following fly stocks were used: dEAAT1-GAL4 and UAS-dEAAT1-GFP (43), moody-GAL4 (41), gliotactin-GAL4 (42), UAS-Httex1p Q93 ( 19 ), UAS-rolledSEM”
BackgroundMethodInfluentialSpinocerebellar ataxias caused by polyglutamine expansions: A review of therapeutic strategies
Underwood, B. R., & Rubinsztein, D. C. (2008) · The Cerebellum · doi:10.1007/s12311-008-0026-z · Cited by 44
“HD fly and mouse models treated with histone deacetylase inhibitors show improved neuropathology and motor phenotypes ( 35 ,36,37).”
BackgroundBeconi, M., Aziz, O., Matthews, K., Moumné, L., O’Connell, C., Yates, D., Clifton, S., Pett, H., Vann, J., Crowley, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044498 · Cited by 42
“Indeed, broad-spectrum HDAC inhibitors partially rectify the transcriptional dysregulation in HD cell and animal models [17–23], enhance the degradation of mHTT by altering the acetylation state of key residues within the protein [24–27], and improve cognition through enhancement of learning and memory processes [28,2…”
Shiwaku, H., & Okazawa, H. (2015) · Current Molecular Medicine · doi:10.2174/1566524015666150303002556 · Cited by 46
“HDAC inhibitors, such as SAHA (suberoylanilide hydroxamic acid) and phenylbutyrate, have been shown to rescue the phenotypes of mouse and fly models of HD [12, 141].”
BackgroundInfluentialDeutsch, S. I., Rosse, R. B., Mastropaolo, J. P., Long, K. D., & Gaskins, B. L. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318067e255 · Cited by 49
“loss of rhabdomeres from their normal complement and arrangement of 7 as they aged, and early adult death.(12) Rearing larvae on sodium butyrate and SAHA or even feeding these HDAC inhibitors to adult flies after their emergence from the pupal case arrested progressive degeneration of photo-”
BackgroundInfluentialDupont, P., Besson, M. T., Devaux, J. J., & Liévens, J.-C. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.04.007 · Cited by 51
Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker?
Lee, J.-H., & Ryu, H. (2010) · BMB Reports · doi:10.5483/bmbrep.2010.43.10.649 · Cited by 46
Walsh, M. J., Cooper‐Knock, J., Dodd, J. E., Stopford, M. J., Mihaylov, S. R., Kirby, J., Shaw, P. J., & Hautbergue, G. M. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12187 · Cited by 43
Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease
Cardinale, A., & Fusco, F. R. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12834 · Cited by 42
Ajamian, F., Salminen, A., & Reeben, M. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.04.087 · Cited by 43
Norflus, F., Nanje, A., Gutekunst, C.-A., Shi, G., Cohen, J., Bejarano, M., Fox, J., Ferrante, R. J., & Hersch, S. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.011 · Cited by 42
Clearance of Mutant Proteins as a Therapeutic Target in Neurodegenerative Diseases
Krainc, D. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.40 · Cited by 45
“Recent studies demonstrate that mutant Htt interacts directly with the histone acetyltransferase (HAT) domain of CBP.(29) Previous studies also demonstrated that depletion of CBP enhanced toxicity, whereas overexpression of CBP suppressed toxicity by mutant Htt.”
BackgroundKandasamy, M., Reilmann, R., Winkler, J., Bogdahn, U., & Aigner, L. (2011) · Neurology Research International · doi:10.1155/2011/124256 · Cited by 46
“HDAC inhibition by HDAC inhibitors might partially restore the transcriptional loss in the HD brain [141, 142].”
BackgroundEpigenetics in Nucleotide Repeat Expansion Disorders
He, F., & Todd, P. K. (2011) · Seminars in Neurology · doi:10.1055/s-0031-1299786 · Cited by 51
“Consistent with this, in both Drosophila and mouse models of HD, broad spectrum HDAC inhibitors suppress neuronal degeneration and reduce lethality.(129,138)Attempts to narrow the spectrum of such agents in a Drosophila disease model suggest that inhibition of sir2 (akin to the mammalian HDAC SIRT1) and RPD3 (akin to…”
BackgroundTechniques: fruit flies as models for neuropharmacological research
Manev, H., Dimitrijević, N., & Dzitoyeva, S. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)00004-4 · Cited by 48
Studying polyglutamine diseases in Drosophila
Xu, Z., Tito, A. J., Rui, Y., & Zhang, S. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.08.002 · Cited by 50
Epigenetic mechanisms governing the process of neurodegeneration
Qureshi, I., & Mehler, M. F. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.06.011 · Cited by 47
“…indications, have shown significant ability to mitigate neurodegeneration in preclinical studies (Biermann et al., 2011; Chen et al., 2009; Colussi et al., 2010; Hahnen et al., 2008; Mai et al., 2009; Ryu et al., 2003; Smith et al., 2010; Steffan et al., 2001; Suzuki, 2009; Zhao et al., 2006).”
BackgroundCollier, T. J., Srivastava, K. R., Justman, C., Grammatopoulous, T., Hutter-Paier, B., Prokesch, M., Havas, D., Rochet, J.-C., Liu, F., Jock, K., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.07.007 · Cited by 41
Small molecule drug discovery for Huntington's Disease
Fecke, W., Gianfriddo, M., Gaviraghi, G., Terstappen, G. C., & Heitz, F. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.006 · Cited by 48
Mallik, M., & Lakhotia, S. C. (2009) · RNA Biology · doi:10.4161/rna.6.4.9268 · Cited by 48
“Following fly stocks were used in the present study: (1) Wild type (Oregon R+) (2) w/w; UAS-20Q/CyO; +/+26 (3) w/w; UAS-127Q/UAS-127Q; +/+26 (4) w/w; UAS-MJDtr-Q27/UAS-MJDtr-Q27; +/+27 (5) w/w; UAS-MJDtr-Q78(S)/UAS-MJDtr-Q78(S); +/+ (SCA3)27 (6) w/w; UAS-httex1p Q20/CyO; +/+65 (7) w/w; UAS-httex1p Q93/CyO; +/+ (HD)65…”
Class IIa histone deacetylases affect neuronal remodeling and functional outcome after stroke
Kassis, H., Shehadah, A., Li, C., Zhang, Y., Cui, Y., Roberts, C. J., Sadry, N., Liu, X., Chopp, M., & Zhang, Z. G. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.04.006 · Cited by 42
“Histone acetylation is a major epigenetic regulatory mechanism implicated in a large number of neuropathological conditions ranging from Huntington’s disease (Steffan et al., 2001), amyotrophic lateral sclerosis (Ryu et al.”
BackgroundDillin, A., & Kelly, J. W. (2007) · Science · doi:10.1126/science.1146585 · Cited by 38
Yohrling, G. J., Farrell, L. A., Hollenberg, A. N., & Cha, J.-H. J. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00032-0 · Cited by 48
Ultrastructure of nuclear aggregates formed by expressing an expanded polyglutamine
Hazeki, N., Tsukamoto, T., Yazawa, I., Koyama, M., Hattori, S., Someki, I., Iwatsubo, T., Nakamura, K., Goto, J., & Kanazawa, I. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00498-9 · Cited by 40
Quinti, L., Chopra, V., Rotili, D., Valente, S., Amore, A. M., Franci, G., Meade, S., Valenza, M., Altucci, L., Maxwell, M. M., et al. (2010) · PLoS Currents · doi:10.1371/currents.rrn1172 · Cited by 44
“In contrast to their marked activity in invertebrate HD models, pan-HDAC inhibitors like SAHA (suberoylanilide hydroxamic acid) or phenyl butyrate have shown only modest efficacy in mouse models [3] [5] [15].”
BackgroundSelf-citationPQBP-1 transgenic mice show a late-onset motor neuron disease-like phenotype
Okuda, T., Hattori, H., Takeuchi, S., Shimizu, J., Ueda, H., Palvimo, J. J., Kanazawa, I., Kawano, H., Nakagawa, M., & Okazawa, H. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg084 · Cited by 40
“HAT disturbance is implicated in the pathology, because suppression of the counteracting enzymes (HDACs) prevents neuronal death in the cell culture and Drosophila models ( 23 ,24).”
BackgroundTulino, R., Benjamin, A. C., Jolinon, N., Smith, D. L., Chini, E. N., Carnemolla, A., & Bates, G. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0145425 · Cited by 42
“We would not expect the increase in P53 acetylation to be caused by the HD-related dysregulation of acetyltransferases as it has been shown that the P53 acetyltransferases: CREB binding protein, P300 and P300/CBP associated factor, are inhibited with disease progression in HD [49] and would therefore be expected to re…”
ResultCognitive dysfunction in H untington's disease: mechanisms and therapeutic strategies beyond BDNF
Puigdellívol, M., Saavedra, A., & Pérez‐Navarro, E. (2016) · Brain Pathology · doi:10.1111/bpa.12432 · Cited by 40
Lee, J.-H., Hwang, Y. J., Kim, Y., Lee, M. Y., Hyeon, S. J., Lee, S., Kim, D. H., Jang, S. J., Im, H., Min, S., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1732-8 · Cited by 45
Meisel, A., Harms, C., Yildirim, F., Bösel, J., Kronenberg, G., Harms, U., Fink, K., & Endres, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04016.x · Cited by 41
“(2006) 98, 1019–1031 1019 et al. 2001; Steffan et al. 2001; Ferrante et al. 2003; Hockly et al. 2003) and status epilepticus (Huang et al. 2002).”
BackgroundMcLear, J. A., Lebrecht, D., Messer, A., & Wolfgang, W. J. (2008) · The FASEB Journal · doi:10.1096/fj.07-099689 · Cited by 39
“The human htt exon 1 with a 20 polyQ repeat (UAS-htt exon-1-Q20) and UAS-htt exon-1-Q93 flies have been described and contain the entire exon 1 from htt harboring the polyQ region (13).”
BackgroundMethodInfluentialHuntington's disease: progress and potential in the field
Stack, E. C., & Ferrante, R. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1933 · Cited by 39
“The HDACi’s sodium butyrate or suberoylanilide hydroxamic acid (SAHA) in a Drosophila model of HD, provides significant neuroprotection [105] .”
BackgroundMinamiyama, M., Katsuno, M., Adachi, H., Doi, H., Kondo, N., Iida, M., Ishigaki, S., Fujioka, Y., Matsumoto, S., Miyazaki, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2932 · Cited by 43
Connecting the dots in Huntington's disease with protein interaction networks.
Giorgini, F., & Muchowski, P. J. (2005) · Genome biology · doi:10.1186/gb-2005-6-3-210 · Cited by 45
“histone deacetylases reverses neurodegeneration in fly models of polyQ disease [12] and improves motor deficits in”
BackgroundIKKα and IKKβ Regulation of DNA Damage-Induced Cleavage of Huntingtin
Khoshnan, A., Ko, J., Tescu, S., Brundin, P., & Patterson, P. H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005768 · Cited by 46
“Enhancement of the histone acetyltransferase activity of CBP is known to reduce the toxicity of mutant Htt [43].”
BackgroundShaw, J. L., & Chang, K. T. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003792 · Cited by 38
Xiang, C., Zhang, S., Dong, X., Ma, S., & Cong, S. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00153 · Cited by 43
“Ström et al. (2005) demonstrated that the transcription mediated by CBP was repressed by expanded ataxin-7.”
BackgroundInfluentialEpigenetic regulation in Huntington's disease
Hyeon, J. W., Kim, A. H., & Yano, H. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105074 · Cited by 42
Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma
Nawar, N., Bukhari, S., Adile, A., Suk, Y., Manaswiyoungkul, P., Toutah, K., Olaoye, O. O., Raouf, Y. S., Sedighi, A., Garcha, H. K., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01585 · Cited by 38
BAG1 modulates huntingtin toxicity, aggregation, degradation, and subcellular distribution
Sroka, K., Voigt, A., Deeg, S., Reed, J. C., Schulz, J. B., Bähr, M., & Kermer, P. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06363.x · Cited by 41
Lisowski, P., Lickfett, S., Rybak‐Wolf, A., Menacho, C., Le, S., Pentimalli, T. M., Notopoulou, S., Dykstra, W., Oehler, D., López-Calcerrada, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51216-w · Cited by 54
“Among these factors, SIN3A and YAP1 may be particularly interesting, given that SIN3A function counteracted neurodegeneration in a drosophila model of HD 85 , and YAP1 was found dysregulated in HD mice and in post-mortem patient brain 79 .”
BackgroundZhu, X., Singh, N., Donnelly, C. J., Boimel, P. J., & Elefant, F. (2007) · Genetics · doi:10.1534/genetics.106.063685 · Cited by 45
“HATs execute acetylation profiles required for target gene regulation and thus their misregulation is linked to numerous types of cancers and developmental defects (Petrij et al. 1995; Mahlknecht et al. 2000; Steffan et al. 2001; Roelfsema et al. 2005; Close et al. 2006).”
BackgroundChan, W. M., Tsoi, H., Wu, C. C., Wong, C. H., Cheng, T. C., Li, H. Y., Lau, K. F., Shaw, P. C., Perrimon, N., & Chan, H. Y. E. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr049 · Cited by 37
Popiel, H. A., Takeuchi, T., Burke, J. R., Strittmatter, W. J., Toda, T., Wada, K., & Nagai, Y. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0184-7 · Cited by 39
Symptomatic and Disease-Modifying Therapy for the Progressive Ataxias
Perlman, S. (2004) · The Neurologist · doi:10.1097/01.nrl.0000141651.35193.67 · Cited by 44
“inhibitors (suberoylanilide hydroxamic acid/SAHA, phenylbutyrate, valproic acid) as candidate agents to up-regulate genes whose expression might have been suppressed by the polyQ gene product.(66,67) Small interfering RNA technology, targeted to the disease mutation or a linked single-nucleotide”
BackgroundYeast, Flies, Worms, and Fish in the Study of Human Disease
Hariharan, I. K., & Haber, D. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmon023158 · Cited by 45
Li, Y., & Alam, H. B. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-5638-5_11 · Cited by 37
“Indeed, perturbation of acetylation homeostasis is being recognized as a central event in the pathogenesis of neurodegeneration and HDAC inhibitors (HDACI) to be protective in animal models of Huntington’s disease (Steffan et al. 2001; McCampbell et al. 2001; Ferrante et al. 2003; Hockly et al. 2003), amyotrophic late…”
BackgroundModulation of Molecular Chaperones in Huntington’s Disease and Other Polyglutamine Disorders
Reis, S., Pinho, B. R., & Oliveira, J. M. A. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0120-z · Cited by 43
Glycation potentiates neurodegeneration in models of Huntington’s disease
Miranda, H. V., Gomes, M. A., Branco‐Santos, J., Breda, C., Lázaro, D. F., Lopes, L. V., Herrera, F., Giorgini, F., & Outeiro, T. F. (2016) · Scientific Reports · doi:10.1038/srep36798 · Cited by 40
Muñoz, E., Rey, M. J., Milà, M., Cardozo, A., Ribalta, T., Tolosa, E., & Ferrer, I. (2002) · Journal of Neurological Sciences · doi:10.1016/s0022-510x(02)00110-7 · Cited by 36
“Interestingly, it has been found that the cell death induced by nuclear accumulation of polyglutamines can be mitigated by overexpression of full-length CREB-binding protein [27] or by the administration of other inhibitors of histone deacetylase [26].”
BackgroundThe Clinical Relevance of Steroid Hormone Receptor Corepressors
Kumar, R., Gururaj, A. E., Vadlamudi, R. K., & Rayala, S. K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1276 · Cited by 40
Huntington's disease: the past, present, and future search for disease modifiers.
Clabough, E. B. D. (2013) · PubMed Central · Cited by 45
Clinical Features and Molecular Mechanisms of Spinal and Bulbar Muscular Atrophy (SBMA)
Katsuno, M., Banno, H., Suzuki, K., Adachi, H., Tanaka, F., & Sobue, G. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6448-9_6 · Cited by 38
Epigenetics, fragile X syndrome and transcriptional therapy
Tabolacci, E., & Chiurazzi, P. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36264 · Cited by 40
“…effect would be actually desirable as in cancer treatments [Gnyszka et al., 2013] or in treatment of polyglutamine expansion disorders, where global histone hypoacetylation seems to play a prominent role [Steffan et al., 2001;Bodai et al., 2012;Pirooznia and Elefant, 2013; Valor et al., 2013].”
BackgroundKoon, A. C., & Chan, H. Y. E. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00070 · Cited by 37
“In the Drosophila model of SCA3, it has been demonstrated that U2AF65, which is involved in the nuclear export of mRNA, can bind directly to CAG repeats and form a complex with the nuclear export receptor NXF1 (Tsoi et al., 2011), and the downregulation of U2AF65 correlates with the nuclear accumulation of expanded CA…”
BackgroundInfluentialNandi, N., Tyra, L. K., Stenesen, D., & Krämer, H. (2017) · eLife · doi:10.7554/elife.30760 · Cited by 33
“UAS-Htt-exon1-Q93, ( Steffan et al., 2001 ), abbreviated UAS-Htt.”
Altered Expression of the NoncodinghsrωGene Enhances poly-Q Induced Neurotoxicity inDrosophila
Sengupta, S., & Lakhotia, S. C. (2006) · RNA Biology · doi:10.4161/rna.3.1.2559 · Cited by 40
Identification of novel targets for PGC-1α and histone deacetylase inhibitors in neuroblastoma cells
Cowell, R. M., Talati, P., Blake, K. R., Meador‐Woodruff, J. H., & Russell, J. W. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.12.109 · Cited by 40
“HDAC inhibitors have been proposed to be a good potential therapeutic agent in the treatment of polyglutamine disorders, including HD [11], and HDAC inhibitors have been successful in improving symptoms and cell survival in drosophila and mouse models of HD [12;13;14;15;16].”
Background
Metadata
- Authors
- Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., Kurokawa, R., Housman, D. E., Jackson, G. R., Marsh, J. L., & Thompson, L. M.
- Affiliations
- University of California, Irvine (US)
- National Institutes of Health (US)
- Massachusetts Institute of Technology (US)
- University of California San Diego (US)
- University of California, Los Angeles (US)
- Corresponding author
- Thompson, Leslie M.
- ORCID
- Venue
- Nature
- Published
- 2001-10
- Volume
- 413
- Issue
- 6857
- Pages
- 739-743
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1643390591
- Cited by
- 1,228
- References
- 28
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 35 · 2020: 35 · 2019: 30 · 2018: 37 · 2017: 34 · 2016: 40 · 2015: 46 · 2014: 63 · 2013: 65 · 2012: 55
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Hereditary Disease Foundation
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- histone deacetylase inhibitors, polyglutamine expansion, Huntington's disease, neurodegeneration, huntingtin exon 1, CREB-binding protein, P300, PCAF, histone acetylation, histone deacetylase, Drosophila model, transcriptional dysregulation
- MeSH terms
- Huntingtin Protein, Acetylation, Acetyltransferases, Animals, Disease Models, Animal, Drosophila, Enzyme Inhibitors, Gene Expression Regulation, Glutamine, Glutathione Transferase, Histone Deacetylases, Histones, Huntington Disease, Nerve Degeneration, Nerve Tissue Proteins, Nuclear Proteins, Peptides, Repressor Proteins, Trans-Activators, PC12 Cells, Protein Structure, Tertiary, Neurodegenerative Diseases, Repetitive Sequences, Amino Acid, Saccharomyces cerevisiae Proteins, Drosophila Proteins, Animals, Genetically Modified, E1A-Associated p300 Protein, CREB-Binding Protein, Rats, Histone Acetyltransferases, Sin3 Histone Deacetylase and Corepressor Complex, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.